Elanco Companion Animal Health has launched a new ordering process for Recuvyra, its transdermal fentanyl solution for the control of postoperative pain relief in dogs.
According to the company, the new process will enable veterinary practices to purchase Recuvyra without having to complete the online training programme that has been mandatory since April 2013.
Despite this change, Elanco said the training is “highly recommended” for every veterinary professional that handles Recuvyra, as it has an “innovative” delivery system. This can be via the short online training course available at www.recuvyratraining.eu or by reading the training leaflet provided with every vial of Recuvyra purchased.
Recuvyra product manager Alice Laurens said: “Veterinary practices will still need to follow their wholesalers’ procedures for ordering schedule two controlled drugs when purchasing Recuvyra. However, any vet from the practice can now order and sign for delivery of the product, making it easier to purchase.”
According to Elanco, Recuvyra is the first veterinary product to make use of Medistend technology. Its unique formulation, said the company, provides long-lasting analgesia by rapidly establishing a depot of fentanyl within the lipid layer of the stratum corneum. The fentanyl in this depot undergoes passive diffusion down a concentration gradient, and is steadily released into the general circulation.
Recuvyra is also the latest product in Elanco’s surgery and pain management range, which also includes the alpha-2 agonists Dexdomitor 0.1, Dexdomitor, Domitor and alpha-2 antagonist Antisedan.
For further information on Recuvyra or Elanco’s surgery and pain management range, email email@example.com or please contact your Elanco Companion Animal Health key account manager.